288 related articles for article (PubMed ID: 30426615)
1. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
Liang C; Ma Y; Yong L; Yang C; Wang P; Liu X; Zhu B; Zhou H; Liu X; Liu Z
Cancer Sci; 2019 Jan; 110(1):166-179. PubMed ID: 30426615
[TBL] [Abstract][Full Text] [Related]
2. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
[TBL] [Abstract][Full Text] [Related]
4. YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia.
Li H; Zhang D; Fu Q; Wang S; Wang Z; Zhang X; Chen X; Zhu X; An N; Chen Y; Zhou L; Lu D; Zhao N
Blood Adv; 2023 Sep; 7(17):4874-4885. PubMed ID: 37339496
[TBL] [Abstract][Full Text] [Related]
5. YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
Zhao S; Wang Y; Guo T; Yu W; Li J; Tang Z; Yu Z; Zhao L; Zhang Y; Wang Z; Wang P; Li Y; Li F; Sun Z; Xuan Y; Tang R; Deng WG; Guo W; Gu C
Oncotarget; 2016 Dec; 7(50):82139-82157. PubMed ID: 27384875
[TBL] [Abstract][Full Text] [Related]
6. Loss of CDH1 up-regulates epidermal growth factor receptor via phosphorylation of YBX1 in non-small cell lung cancer cells.
Liu X; Su L; Liu X
FEBS Lett; 2013 Dec; 587(24):3995-4000. PubMed ID: 24211838
[TBL] [Abstract][Full Text] [Related]
7. Aldolase A promotes proliferation and G
Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker.
Zhao X; Liu Y; Yu S
Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1805-1816. PubMed ID: 28428004
[TBL] [Abstract][Full Text] [Related]
9. The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-κB signaling axis.
Wang Y; Su J; Wang Y; Fu D; Ideozu JE; Geng H; Cui Q; Wang C; Chen R; Yu Y; Niu Y; Yue D
J Exp Clin Cancer Res; 2019 Sep; 38(1):386. PubMed ID: 31481087
[TBL] [Abstract][Full Text] [Related]
10. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.
Magnaghi P; Salom B; Cozzi L; Amboldi N; Ballinari D; Tamborini E; Gasparri F; Montagnoli A; Raddrizzani L; Somaschini A; Bosotti R; Orrenius C; Bozzi F; Pilotti S; Galvani A; Sommer J; Stacchiotti S; Isacchi A
Mol Cancer Ther; 2018 Mar; 17(3):603-613. PubMed ID: 29237806
[TBL] [Abstract][Full Text] [Related]
11. RP11-296E3.2 acts as an important molecular chaperone for YBX1 and promotes colorectal cancer proliferation and metastasis by activating STAT3.
Shi Q; He Y; He S; Li J; Xia J; Chen T; Huo L; Ling Y; Liu Q; Zang W; Wang Q; Tang C; Wang X
J Transl Med; 2023 Jun; 21(1):418. PubMed ID: 37370092
[TBL] [Abstract][Full Text] [Related]
12. Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1.
Zhou X; Zhang K; Wang C; Teng Y; Yu P; Cai W; Gao W; Li M; Ding Y; Sun P; Chen F; Wang Y; Ma J; Maeshige N; Ma X; Li Q; Liang X; Zhang Y; Su D
Cancer Lett; 2024 May; 590():216868. PubMed ID: 38593920
[TBL] [Abstract][Full Text] [Related]
13. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
14. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1.
Lin Y; Zhang J; Li Y; Guo W; Chen L; Chen M; Chen X; Zhang W; Jin X; Jiang M; Xiao H; Wang C; Song C; Fu F
J Transl Med; 2022 Jan; 20(1):17. PubMed ID: 34991621
[TBL] [Abstract][Full Text] [Related]
15. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
16. USP18 promotes breast cancer growth by upregulating EGFR and activating the AKT/Skp2 pathway.
Tan Y; Zhou G; Wang X; Chen W; Gao H
Int J Oncol; 2018 Jul; 53(1):371-383. PubMed ID: 29749454
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting CK2α and YBX1 suppresses tumor progression by coordinated inhibition of the PI3K/AKT signaling pathway.
Xu WF; Ma YC; Ma HS; Shi L; Mu H; Ou WB; Peng J; Li TT; Qin T; Zhou HM; Fu XQ; Li XH
Cell Cycle; 2019 Dec; 18(24):3472-3490. PubMed ID: 31713447
[TBL] [Abstract][Full Text] [Related]
18. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer.
Kuwano M; Shibata T; Watari K; Ono M
Cancer Sci; 2019 May; 110(5):1536-1543. PubMed ID: 30903644
[TBL] [Abstract][Full Text] [Related]
20. Targeting Phosphorylation of Y-Box-Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance.
Shibata T; Watari K; Kawahara A; Sudo T; Hattori S; Murakami Y; Izumi H; Itou J; Toi M; Akiba J; Akagi Y; Tanaka M; Kuwano M; Ono M
Mol Cancer Ther; 2020 Mar; 19(3):882-894. PubMed ID: 31879363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
